Astellas To Explore IBS Endpoints Before Advancing Ramosetron Into Phase III
This article was originally published in The Pink Sheet Daily
Japanese pharma hopes its novel 5-HT3 antagonist will enter Phase III trials in 2008 after completion of an FDA-requested study of endpoints used in irritable bowel syndrome trials.
You may also be interested in...
But multinationals may be increasingly squeezed out of Japanese deals due to the merger wave, company exec tells BIO-Asia conference in Tokyo.
Company also inks monoclonal antibody deal with Kirin Brewery.
Company takes a more bullish stance on its COX-2 inhibitor than Merck, which has assumed FDA approval of its Vioxx follow-on product Arcoxia in 2007.